Education
About Us
Working with TipRanks
Follow Us
NextCell Pharma AB (SE:NXTCL)
:NXTCL
RESEARCH TOOLSreports
Total Valuation
NextCell Pharma AB has a market cap or net worth of kr132.11M. The enterprise value is kr62.23M.
Market Capkr132.11M
Enterprise Valuekr62.23M
Share Statistics
NextCell Pharma AB has 111,392,960 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding111,392,960
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
NextCell Pharma AB’s return on equity (ROE) is -0.62 and return on invested capital (ROIC) is -60.45%.
Return on Equity (ROE)-0.62
Return on Assets (ROA)-0.52
Return on Invested Capital (ROIC)-60.45%
Return on Capital Employed (ROCE)-0.60
Revenue Per Employee444.36K
Profits Per Employee-1.75M
Employee Count24
Asset Turnover0.13
Inventory Turnover27.92
Valuation Ratios
The current PE Ratio of NextCell Pharma AB is ―. NextCell Pharma AB’s PEG ratio is 1.28.
PE Ratio―
PS Ratio8.70
PB Ratio1.37
Price to Fair Value1.37
Price to FCF-2.45
Price to Operating Cash Flow-2.40
PEG Ratio1.28
Income Statement
In the last 12 months, NextCell Pharma AB had revenue of 10.66M and earned -41.96M in profits. Earnings per share was -0.57.
Revenue10.66M
Gross Profit-4.56M
Operating Income-43.17M
Pretax Income-41.96M
Net Income-41.96M
EBITDA-40.99M
Earnings Per Share (EPS)-0.57
Cash Flow
In the last 12 months, operating cash flow was -36.05M and capital expenditures -2.45M, giving a free cash flow of -38.49M billion.
Operating Cash Flow-36.05M
Free Cash Flow-38.49M
Free Cash Flow per Share-0.35
Dividends & Yields
NextCell Pharma AB pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta-0.29
52-Week Price Change-17.61%
50-Day Moving Average1.07
200-Day Moving Average1.98
Relative Strength Index (RSI)55.87
Average Volume (3m)430.08K
Important Dates
NextCell Pharma AB upcoming earnings date is Oct 30, 2025, TBA (Confirmed).
Last Earnings DateJul 24, 2025
Next Earnings DateOct 30, 2025
Ex-Dividend Date―
Financial Position
NextCell Pharma AB as a current ratio of 6.14, with Debt / Equity ratio of 0.00%
Current Ratio6.14
Quick Ratio6.09
Debt to Market Cap0.00
Net Debt to EBITDA1.14
Interest Coverage Ratio-31.81K
Taxes
In the past 12 months, NextCell Pharma AB has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
NextCell Pharma AB EV to EBITDA ratio is -1.12, with an EV/FCF ratio of -1.22.
EV to Sales4.32
EV to EBITDA-1.12
EV to Free Cash Flow-1.22
EV to Operating Cash Flow-1.22
Balance Sheet
NextCell Pharma AB has kr16.71M in cash and marketable securities with kr0.00 in debt, giving a net cash position of -kr16.71M billion.
Cash & Marketable Securitieskr16.71M
Total Debtkr0.00
Net Cash-kr16.71M
Net Cash Per Share-kr0.15
Tangible Book Value Per Sharekr0.92
Margins
Gross margin is -125.13%, with operating margin of -404.81%, and net profit margin of -393.45%.
Gross Margin-125.13%
Operating Margin-404.81%
Pretax Margin-393.45%
Net Profit Margin-393.45%
EBITDA Margin-384.31%
EBIT Margin-393.45%
Analyst Forecast
The average price target for NextCell Pharma AB is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast-17.91%
EPS Growth Forecast22.80%